Genenta Science S.p.A.

GNTA Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2019–FY2025

Revenue

—

vs prior year

Operating margin

—

Net income

−$7.4M

Free cash flow

−$7.8M

Return on capital

—

Market cap

—

P/E

—

On −$0.37 EPS (TTM)

What Genenta Science S.p.A. does

No business description yet.

Legal name: Genenta Science S.p.A.
Fiscal year ends: December 31, 2025
Latest annual report: 20-F · Apr 1, 2026
Accession · CIK: 0001493152-26-014387
0001838716

Revenue and margins

Genenta Science S.p.A. had — of revenue in fiscal 2025.

Revenue

FY19

Revenue —

FY20

Revenue —

FY21

Revenue —

FY22

Revenue —

FY23

Revenue —

FY24

Revenue —

FY25

Revenue —

Margins, % of revenue

FY19

Gross —

Operating —

Net —

FCF —

FY20

Gross —

Operating —

Net —

FCF —

FY21

Gross —

Operating —

Net —

FCF —

FY22

Gross —

Operating —

Net —

FCF —

FY23

Gross —

Operating —

Net —

FCF —

FY24

Gross —

Operating —

Net —

FCF —

FY25

Gross —

Operating —

Net —

FCF —

Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income

FY19

Net income −$5.1M

FY20

Net income −$6.4M

FY21

Net income −$6.5M

FY22

Net income −$8.9M

FY23

Net income −$12.6M

FY24

Net income −$9.6M

FY25

Net income −$7.4M

Diluted EPS

FY19

Diluted EPS —

FY20

Diluted EPS —

FY21

Diluted EPS −$0.44

FY22

Diluted EPS −$0.49

FY23

Diluted EPS −$0.69

FY24

Diluted EPS −$0.53

FY25

Diluted EPS −$0.37

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)

FY19

Return on capital —

Return on equity −24.3%

Return on assets —

FY20

Return on capital —

Return on equity −32.1%

Return on assets −29.7%

FY21

Return on capital —

Return on equity −20.9%

Return on assets −19.6%

FY22

Return on capital —

Return on equity −23.1%

Return on assets −22.0%

FY23

Return on capital —

Return on equity −45.1%

Return on assets −41.7%

FY24

Return on capital —

Return on equity −54.2%

Return on assets −48.1%

FY25

Return on capital —

Return on equity −38.1%

Return on assets −27.9%

Return on capital Return on equity Return on assets

Cash flow

Free cash flow was −$7.8M in fiscal 2025, — of revenue. Cash from operations minus capital spending.

Free cash flow

FY19

Free cash flow —

FY20

Free cash flow −$6.9M

FY21

Free cash flow −$8.2M

FY22

Free cash flow −$7.8M

FY23

Free cash flow −$12.1M

FY24

Free cash flow −$6.8M

FY25

Free cash flow −$7.8M

Cash from operations vs capital spending

FY19

Cash from operations −$2.8M

Capital spending —

FY20

Cash from operations −$6.9M

Capital spending $0.0M

FY21

Cash from operations −$8.2M

Capital spending $0.0M

FY22

Cash from operations −$7.8M

Capital spending $0.0M

FY23

Cash from operations −$12.1M

Capital spending $0.0M

FY24

Cash from operations −$6.8M

Capital spending $0.0M

FY25

Cash from operations −$7.7M

Capital spending $0.0M

Cash from operations Capital spending

Dividends, buybacks and share count

Genenta Science S.p.A. returned — to shareholders in fiscal 2025. The diluted share count rose 7.9%.

Dividends and buybacks

FY19

Dividends —

Buybacks —

FY20

Dividends —

Buybacks —

FY21

Dividends —

Buybacks —

FY22

Dividends —

Buybacks —

FY23

Dividends —

Buybacks —

FY24

Dividends —

Buybacks —

FY25

Dividends —

Buybacks —

Dividends Buybacks

Diluted shares outstanding (annual)

FY19

Diluted shares —

FY20

Diluted shares —

FY21

Diluted shares 0.02B

FY22

Diluted shares 0.02B

FY23

Diluted shares 0.02B

FY24

Diluted shares 0.02B

FY25

Diluted shares 0.02B

Balance sheet

Cash, debt and the ratios that show how comfortably Genenta Science S.p.A. can carry it.

Cash vs debt (incl. leases)

FY19

Cash —

Debt —

FY20

Cash $19.0M

Debt —

FY21

Cash $42.2M

Debt —

FY22

Cash $31.8M

Debt —

FY23

Cash $20.7M

Debt —

FY24

Cash $13.2M

Debt —

FY25

Cash $33.1M

Debt —

Cash Debt

Fiscal year end	FY21	FY22	FY23	FY24	FY25
Cash and short-term investments	$42.2M	$31.8M	$20.7M	$13.2M	$33.1M
Current ratio	34.1x	14.5x	12.2x	6.9x	14.2x
Quick ratio	34.1x	14.5x	12.2x	6.9x	14.2x
Total assets	$45.3M	$35.7M	$24.7M	$15.4M	$37.5M
Total liabilities	$1.3M	$2.5M	$2.1M	$2.4M	$11.8M
Shareholders' equity	$44.0M	$33.2M	$22.6M	$13.0M	$25.7M
Net debt (− = net cash)	—	—	—	—	—

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

Test	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income is positive	✕	✕	✕	✕	✕	✕	✕
Cash from operations is positive	✕	✕	✕	✕	✕	✕	✕
Return on assets rose	—	—	✓	✕	✕	✕	✓
Cash from operations exceeds net income	✓	✕	✕	✓	✓	✓	✕
Debt fell relative to assets	—	—	—	—	—	—	—
Current ratio rose	—	—	✓	✕	✕	✕	✓
Share count didn't rise	—	—	—	✕	✓	✕	✕
Gross margin rose	—	—	—	—	—	—	—
Revenue rose relative to assets	—	—	—	—	—	—	—
F-score	— / 3	— / 3	— / 5	— / 6	— / 6	— / 6	— / 6
Accruals ratio	—	2.4%	5.1%	−2.7%	−1.6%	−14.4%	1.4%
Altman Z''	—	6.09	37.97	14.37	6.60	−5.83	0.28

7 years of figures

Amounts in USD. Hover a ratio’s name for its definition.

Download CSV

Fiscal year	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Income statement
Research and development	$4.1M	$5.3M	$4.0M	$5.6M	$7.0M	$5.2M	$3.0M
Operating income	−$5.2M	−$6.4M	−$6.7M	−$11.6M	−$12.7M	−$10.6M	−$7.4M
Pretax income	−$5.1M	−$6.4M	−$6.5M	−$8.9M	−$12.6M	−$9.6M	−$7.4M
Net income	−$5.1M	−$6.4M	−$6.5M	−$8.9M	−$12.6M	−$9.6M	−$7.4M
Diluted EPS	—	—	−$0.44	−$0.49	−$0.69	−$0.53	−$0.37
Diluted shares	—	—	0.02B	0.02B	0.02B	0.02B	0.02B
Cash flow
Cash from operations	−$2.8M	−$6.9M	−$8.2M	−$7.8M	−$12.1M	−$6.8M	−$7.7M
Capital expenditure	—	$0.0M	$0.0M	$0.0M	$0.0M	$0.0M	$0.0M
Free cash flow	—	−$6.9M	−$8.2M	−$7.8M	−$12.1M	−$6.8M	−$7.8M
Depreciation and amortization	—	$0.0M	$0.0M	$0.0M	$0.0M	$0.0M	$0.0M
Stock-based compensation	$0.8M	$0.5M	$0.6M	$0.8M	$0.8M	$0.9M	$1.1M
Balance sheet
Cash and short-term investments	—	$19.0M	$42.2M	$31.8M	$20.7M	$13.2M	$33.1M
Current assets	—	$20.3M	$43.9M	$33.8M	$23.5M	$15.0M	$35.2M
Current liabilities	—	$2.9M	$1.3M	$2.3M	$1.9M	$2.2M	$2.5M
Property and equipment, net	—	$0.0M	$0.0M	$0.1M	$0.1M	$0.0M	$0.0M
Intangible assets	—	—	—	$0.1M	—	—	—
Total assets	—	$21.5M	$45.3M	$35.7M	$24.7M	$15.4M	$37.5M
Total liabilities	—	$2.9M	$1.3M	$2.5M	$2.1M	$2.4M	$11.8M
Shareholders' equity	$21.2M	$18.6M	$44.0M	$33.2M	$22.6M	$13.0M	$25.7M
Returns
Return on capital employed	—	−34.2%	−15.3%	−34.8%	−55.7%	−79.9%	−21.3%
Return on equity	−24.3%	−32.1%	−20.9%	−23.1%	−45.1%	−54.2%	−38.1%
Return on assets	—	−29.7%	−19.6%	−22.0%	−41.7%	−48.1%	−27.9%
Return on tangible equity	−24.3%	−34.3%	−14.9%	−26.9%	−55.8%	−74.3%	−28.7%
Growth
Share count change	—	—	—	20.8%	0.0%	0.3%	7.9%
Financial health
Current ratio	—	7.1x	34.1x	14.5x	12.2x	6.9x	14.2x
Quick ratio	—	7.1x	34.1x	14.5x	12.2x	6.9x	14.2x
Quality scores
Altman Z''	—	6.1	38.0	14.4	6.6	−5.8	0.3
Accruals ratio	—	2.4%	5.1%	−2.7%	−1.6%	−14.4%	1.4%

Source: SEC EDGAR XBRL filings (CIK 0001838716). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. Filed in EUR under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.